- Home
- ADIL vs DCOY Comparison
ADIL vs DCOY Comparison
Compare ADIL & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.23
N/A
Current Price
$0.90
Company Overview
Basic Information| Metric | ADIL | DCOY |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.8M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADIL | DCOY |
|---|---|---|
| Price | $0.23 | $0.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | 361.9K | ★ 6.2M |
| Earning Date | 03-03-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.51 |
| 52 Week High | $1.30 | $52.95 |
Technical Indicators
Market Signals| Indicator | ADIL | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | N/A |
| Support Level | $0.21 | N/A |
| Resistance Level | $0.24 | N/A |
| Average True Range (ATR) | 0.02 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 32.89 | 0.00 |
Price Performance
Historical Comparison ADIL
DCOY
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About DCOY Decoy Therapeutics Inc. Common Stock
Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.